Enterprise Therapeutics

OverviewSuggest Edit

Enterprise Therapeutics is a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases.
In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlying mechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life.

TypePrivate
Founded2014
HQFalmer, GB
Websiteenterprisetherapeutics.com

Latest Updates

Employees (est.) (Jan 2020)14(-6%)

Key People/Management at Enterprise Therapeutics

John Ford

John Ford

CEO
Amit Munshi

Amit Munshi

Chairman
Martin Gosling

Martin Gosling

Chief Scientific Officer
Paul Russell

Paul Russell

Head of Development
Peter Finan

Peter Finan

Investor Director
David Morris

David Morris

Chief Medical Officer
Show more

Enterprise Therapeutics Office Locations

Enterprise Therapeutics has an office in Falmer
Falmer, GB (HQ)
Science Park Square
Show all (1)

Enterprise Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2014

Enterprise Therapeutics total Funding

$59.6 m

Enterprise Therapeutics latest funding size

$7.26 m

Time since last funding

3 months ago

Enterprise Therapeutics investors

Enterprise Therapeutics's latest funding round in October 2019 was reported to be $7.3 m. In total, Enterprise Therapeutics has raised $59.6 m
Show all financial metrics

Enterprise Therapeutics Revenue

Cash (31-Mar-2018)

172.6k
GBPFY, 2016FY, 2017FY, 2018

Cash

446.9k30.8k172.6k

Accounts Receivable

273.0

Current Assets

461.0k42.9k178.3k
Y, 2018

Financial Leverage

1.6 x
Show all financial metrics

Enterprise Therapeutics Online and Social Media Presence

Embed Graph

Enterprise Therapeutics Blogs

Enterprise Therapeutics publishes paper on novel therapeutic approach for treatment of all cystic fibrosis patients

“TMEM16A Potentiation: A Novel Therapeutic Approach for the Treatment of Cystic Fibrosis” published in American Journal of Respiratory and Critical Care Medicine Paper demonstrates first in class TMEM16A chloride channel potentiators, to accelerate mucociliary clearance Co-authored by researchers fr…

TMEM16A Channel Function Does Not Influence Goblet Cell Numbers or Mucin Secretion In The Human Airway Epithelium – NACFC – Nashville – October 2019

TMEM16A Channel Function Does Not Influence Goblet Cell Numbers or Mucin Secretion In The Human Airway Epithelium – NACFC – Nashville – October 2019 Henry Danahay1,2, Alexis Flen, Camille Ehre3, Martin Gosling1,2 1University of Sussex, Brighton, UK; 2Enterprise Therapeutics, UK; 3University of North…

EACT Increases Intracellular Calcium Levels by a Tmem16a-Independent Mechanism – NACFC – Nashville – October 2019

EACT Increases Intracellular Calcium Levels by a Tmem16a-Independent Mechanism – NACFC – Nashville – October 2019 Sarah Lilley1, Henry Danahay1,2, Holly Charlton1, Kathryn Adley1, Roy Fox1, Martin Gosling1,2 1University of Sussex, Brighton, UK; 2Enterprise Therapeutics, UK The N-aroylaminothiazole E…

The In Vitro & In Vivo Pharmacology of Novel Tmem16a Potentiator Compounds – NACFC – Nashville – October 2019

The In Vitro & In Vivo Pharmacology of Novel Tmem16a Potentiator Compounds – NACFC – Nashville – October 2019 Henry Danahay1,2, Sarah Lilley1, Holly Charlton1, Roy Fox1, Brian Button3, Juan Sabater4, Martin Gosling1,2 1University of Sussex, Brighton, UK; 2Enterprise Therapeutics, UK; 3University…

Enterprise Therapeutics awarded up to £5.7M ($7M) from Cystic Fibrosis Foundation to Support Clinical Development of Novel Chloride Channel Modulator

Support for clinical development up to end of Phase 2 for ETD002, first-in-class TMEM16A potentiator for the treatment of cystic fibrosis Milestone Funding through Cystic Fibrosis Foundation’s Therapeutics Development Award programme Brighton, UK, 15 October 2019: Enterprise Therapeutics Ltd (Enterp…

ECFS Clinical Meeting Liverpool TMEM16A potentiator

ECFS Clinical Meeting Liverpool TMEM16A potentiator Objectives: TMEM16A (ANO1) is a Ca2+-activated, alternative chloride channel expressed in the human airway epithelium. A potentiator of TMEM16A is predicted to enhance the secretion of chloride and thereby increase mucus hydration and clearance in …
Show more

Enterprise Therapeutics Frequently Asked Questions

  • When was Enterprise Therapeutics founded?

    Enterprise Therapeutics was founded in 2014.

  • Who are Enterprise Therapeutics key executives?

    Enterprise Therapeutics's key executives are John Ford, Amit Munshi and Martin Gosling.

  • How many employees does Enterprise Therapeutics have?

    Enterprise Therapeutics has 14 employees.

  • Who are Enterprise Therapeutics competitors?

    Competitors of Enterprise Therapeutics include Inovio Pharmaceuticals, MyoKardia and Athersys.

  • Where is Enterprise Therapeutics headquarters?

    Enterprise Therapeutics headquarters is located at Science Park Square, Falmer.

  • Where are Enterprise Therapeutics offices?

    Enterprise Therapeutics has an office in Falmer.

  • How many offices does Enterprise Therapeutics have?

    Enterprise Therapeutics has 1 office.